The billionaire’s low-cost pharmaceutical company began offering brand name drugs in early March and has added several since.
The addition of Yusimry, manufactured by Coherus BioSciences, to Cost Plus Drugs offerings marks a move by the company to begin “to make biologics accessible to all,” the company said in a tweet.
“We are excited to disrupt the high-cost biologic space by offering Yusimry, a biosimilar of Humira, one of the highest cost drugs in America,” Alex Oshmyansky, co-founder and CEO of Mark Cuban Cost Plus Drug Company said in a statement.
Without insurance, purchasing the drug from Mark Cuban’s pharmacy will cost around $570.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.